eShop
English
Introduction
In 2025, Cobetter launched a new Single-Use Drug Preparation Filter, designed to efficiently remove insoluble particulates during clinical drug preparation. The product has been rapidly adopted in hospitals and clinical environments and has shown strong potential across a variety of application scenarios, including complex and lipid-based formulations.
To support customers facing post-approval change (PAC) and lifecycle management requirements, Cobetter conducted a representative change study using this single-use filter. This article summarizes the key design considerations and evaluation points and is intended as a practical reference for similar change assessments.
Product Overview
Product name: Single-Use Drug Preparation Filter
Model: SFU25VC0500S
Size / rating: 25 mm, 5 μm nominal
Classification: Class II medical device (China NMPA)
Sterility: γ-sterilized, individually packaged
Bacterial retention: Bacterial removal efficiency ≥ 90% (challenge organism Staphylococcus aureus)
The filter is dedicated to point-of-use drug preparation, where insoluble particulates must be effectively removed to help reduce clinical risks such as inflammation and embolism.
Typical Use in Drug Preparation
The Cobetter Single-Use Drug Preparation Filter is designed for straightforward integration into existing clinical workflows:
This configuration minimizes the risk of insoluble particulates while maintaining ease of use at the bedside or in the pharmacy.
Why a Change Study Is Needed
When replacing an existing filter or introducing a new filter into an established product, it is essential to understand how the change may impact the critical quality attributes (CQAs) of the drug product. For complex formulations, this is especially important.
For example, in the case of lipid-based injections, the 2023 edition of the Technical Guideline for Quality Control of Lipid-Based Drugs issued by the China CDE highlights that the following factors can impact safety and efficacy:
- The composition, structure, size and surface properties of the lipid-based drug product
- Drug encapsulation efficiency
- Drug loading
- Excipients and dosage form
- Stability and drug release behavior
- Interactions between lipid carriers and biological membranes
Filtration may influence several of these dimensions. Therefore, any change to the filtration step must be supported by a structured study focusing on relevant CQAs.
Study Design and Key Parameters
In this change study, Cobetter selected representative complex formulations and evaluated three batches of each, comparing conditions with and without the Cobetter Single-Use Drug Preparation Filter.
Product-Related CQAs
In addition to product CQAs, functional aspects of filtration were also evaluated:
- Potential impact of filter dead volume on delivered dose
- Possible adsorption of API and excipients
- Overall injection volume (dose) accuracy after filtration
This assessment ensures that patients receive the intended dose even when a new filter is introduced.
Change Assessment Approach
After filtration, all CQAs and functional parameters were compared with:
- Pre-change data, and
- Established product specifications.
If the evaluation confirms that:
- All specifications continue to be met
- Appearance, particle size distribution, key excipient levels and API content are comparable before and after filtration
- Delivered dose remains within the target accuracy range
- No adverse compatibility or safety concerns are identified
then the filter change can be considered low risk from a quality perspective.
Under widely accepted global regulatory frameworks for post-approval changes, this type of modification may be treated as a minor change and reported via an annual report, rather than requiring classification as a major variation. for post-approval changes to approved drug products, such a change may be managed as a minor change, reported in the form of an annual report, rather than as a major variation. The final regulatory strategy should always be aligned with local regulatory requirements and the specific characteristics of the product.
Conclusion
Cobetter’s Single-Use Drug Preparation Filter (SFU25VC0500S) provides an efficient, easy-to-use solution for controlling insoluble particulates during clinical drug preparation, particularly in complex and lipid-based formulations.
By structuring change studies around clearly defined critical quality attributes and dose accuracy, manufacturers can introduce filter changes with greater confidence, while aligning with regulatory expectations for post-approval change management.
Cobetter is committed to supporting customers in the design and evaluation of single-use solutions across the drug lifecycle, from development through commercialization and lifecycle changes.
